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Abstract 
 
The high failure rates of imported medical devices in developing countries represent a significant 
challenge in the fight against world diseases. Developing affordable devices designed with an 
understanding of health care systems in developing countries is imperative. This project outlines the 
necessary steps for the development of a lab-on-chip microfluidics test for the detection of diarrhoeal 
pathogens. A framework is outlined based on the lessons learnt in implementing medical devices and the 
successes of custom devices designed to meet the needs of the developing world such as auto-disable 
syringes.  
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1. Executive Summary 
 
 The Declaration of Alma-Ata in 1978 by the World Health Organisation (WHO) 
highlighted the importance of appropriate and functioning medical technology in healthcare 
delivery1. Medical devices are an integral part of health care systems as they facilitate healthcare 
delivery, diagnosis and treatment for better patient care. Developing countries account for about 
80% of the world’s population and bear a significant burden (about 93%) of the world’s 
diseases2. However, over 95% of medical equipment in developing countries is imported and 
most don’t often meet the needs of their health care systems3. The WHO estimates that 50% of 
equipment is not in use due to lack of maintenance or spare parts, device over-sophistication or 
lack of proper use by health personnel3.  
Most medical devices are designed for industrialised countries having the high GDP 
spending to back medical expenditure as well as the adequate infrastructure to incorporate these 
devices into their healthcare systems. In addition to this difference in target market in design 
consideration, are socio-economic and regulatory issues that make the application of these 
imported medical devices problematic in developing countries. Unfortunately, designing for the 
developing world market presents unique challenges due to the lack of understanding of 
healthcare systems in developing countries. In addition, there is little incentive for the medical 
device industry to develop products specifically for developing countries due to the non 
guarantee of return of investment4. 
Fortunately, the past few years has seen an increased interest in global health, attracting 
investments from private and non-governmental organisations for the development of 
technologies designed specifically to meet the needs of developing countries. For example, an 
improvement in vaccination coverage and reduction in unsafe injections in developing countries 
has been observed due to the introduction of auto-disable syringes and cold chains in developing 
countries, coordinated by the WHO and other global health organisations. Developing affordable 
devices designed with an understanding of health care systems in developing countries is 
imperative. 
The goal of this project is to develop guidelines for the development and testing of 
medical devices designed to meet the needs of developing countries, specifically for a diagnostic 
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test for the detection of diarrhoeal pathogens. This project will examine through literature search, 
the reasons for the inappropriateness of imported medical devices within the context of 
developing countries to identify the key areas to consider during the design development process. 
In addition, the success of auto-disable syringe implementation in immunisation programs in 
developing countries will serve as a model template to adopt when developing these guidelines. 
This information will be useful to biomedical engineers, and medical device industry who would 
like to consider designing devices for the developing world community.   
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2. Medical Device Challenges in Developing Countries 
2.1. Imported Medical Technology 
2.1.1. Medical Device Market 
The annual global medical device market is worth $150 billion and is expected to grow 
by 4-5% over the next few years due to the current medical technology revolution 1,5,6. About 
50% of all diagnostic and treatment methods used today where nonexistent a decade ago7 and the 
number of medical device patents filed in the U.S. Patent and Trademark Office has more than 
doubled since 19898. The US is a key player in the development of medical devices; it is the base 
for 9 of the top 10 world medical device companies, produces over half of the world’s medical 
devices and consumes about 40%1,5,6.  
Such growth in the medical device industry creates business opportunities that attract 
many medical device suppliers and manufacturers. However, due to the high costs involved in 
developing new medical devices, investors are typically attracted to larger device markets or the 
more established ones like the adult demographic. The increasing ageing population, emerging 
middle class markets, and the (unfortunate) spread of the “Western diet” represents areas with 
unmet clinical needs. Cardiovascular (CDV) and orthopeadics device market are some of the 
leading device markets in most industrialised countries due to the high prevalence of 
cardiovascular disease and the more active lifestyles of the ageing population5. In addition, major 
medical device companies tend to increase their product portfolios by acquisition of smaller 
companies or mergers, as opposed to through internal early stage research and development 5,9.  
Prior to entering a new market, suppliers typically look at industry reports to estimate 
potential market demand and forecast profits. China’s market has been projected to grow faster 
than the global medical device market. The reasons for this fast growth include its fast growing 
domestic economy, increased GDP spending on healthcare, increased demand for more advanced 
medical technologies, the availability of health insurance as well as increased government focus 
on improving healthcare in the country10. Although a majority of the Indian population cannot 
afford healthcare, its growing middle and upper class population (+150 million people) is a 
promising market due to their changing disease profiles i.e. more sedentary lifestyles and rise in 
CDV diseases11.  Developing countries represent the fastest growing medical device market due 
to their greater disease burden, with a market size about five times of the developed world12. 
11 
 
Unfortunately, although developing countries account for about 80% of the world's 
population and 93% of the world’s disease burden, they contribute to only 10-11% percent of 
total healthcare spending2. Ironically, most of the world’s population requiring health services 
are forced to use medical devices designed for high income countries. Over 95% of medical 
equipment in developing countries is imported and the WHO estimates that 70% of this 
equipment doesn’t work because they don’t meet their healthcare needs3,12. This “bundle, 
package and ship” form of technology transfer without considering the internal capabilities to 
accept, diffuse, produce and manage medical technology is mainly responsible for this failure of 
most medical devices in the developing world. Developing countries are thus faced with the 
challenge of adapting these technologies into their health care systems with direct implications 
on the appropriateness of these technologies.  
There is thus the need to balance this largely supply-driven market and meeting the actual 
needs of the healthcare population. Despite the wide array of medical devices, this supply-driven 
market has created inequitable access to medical equipment, especially for countries with small 
populations, weak socio-economic situations or unstable political conditions. This huge 
technology divide is thus problematic as deriving maximum benefits from medical devices 
requires technical knowledge, skills and operation resources which may not be available in most 
developing countries. The high costs of medical devices can be made more affordable for most 
developing countries if cost is factored as a main design consideration during the device 
development process.  
Opening a market requires a considerable amount of investment as well as research and 
development to adapt or develop new products to local conditions e.g. climate, access to 
electricity and water, transportation conditions etc. Most medical devices assume an existing 
minimal infrastructure level of electricity and water (e.g. distilled or deionised). For example, 
although x-ray imaging has existed for more than a century, the unreliability of power in most 
developing country hospitals makes them impractical for use. In addition to being very 
expensive, MRI imaging use is unfeasible due to its high power consumption. There is often 
little local production of medical equipment in most developing countries and if any, it is 
controlled by multinational corporations with little commitment to local research and 
development. Setting up production facilities can sometimes be difficult due to import 
restrictions, transportation and tariff costs. Investors can also be discouraged that their large 
investment cannot be supported by the market in developing countries13. 
 Equipment service organisations thus play a significant role in these countries to serve as 
a bridge between medical device manufacturers and buyers as they provide the necessary 
information for product purchase, supply spare parts, train buyers to use the product etc. 
However, the limited number of these organisations can be problematic 13 . Unfortunately, 
as Figure 1 shows, while a hospital in the U.S. readily available information and the luxury of 
various choice options prior to making equipment purchase, most developing countries lack this 
information to help in their decision making and are often faced with only one manufacturer 
option. This lack of choice in selecting and negotiating suitable terms with suppliers makes them 
more susceptible to being locked into long contracts as well as inflated prices for services. 
Robert Malkin notes that the lack of spare parts due to insufficient number of local suppliers in 
most development significantly reduces the life cycle of medical devices, especially when a first 
replacement is required12 (see Appendix A for medical device acquisition flow chart14). 
 
 
 
 
 
 
 
 
 
 
Figure 1:  Comparison of equipment selection scenarios between developing 
and developed countries 15 
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2.1.2. Medical Device Donations 
Due to the high costs of healthcare, donour assistance and foreign aid represents a 
significant portion of healthcare funding in most developing countries. In 1990, total aid to the 
healthcare sector was estimated at $4.8 billion, with over 80% coming as development assistance 
and the rest through foundations and other sources. In Burkina Faso, Chad, Guinea-Bissau, 
Mozambique, and Tanzania, foreign aid covers over half of all health expenditures16. For most 
donours, medical device donations allow for frequent equipment turnover, tax deductions, or 
better yet the good benefactor feel of helping people in need. For developing countries, it allows 
for quicker access to sophisticated technology that might be otherwise unaffordable. 
Despite significant investment, this “technical invasion” has led to the inefficient use of 
most medical device in developing country settings.  Investments in expensive equipments with 
no clear benefits have often proven to be unsustainable as they distort healthcare spending 
patterns. For example, in the early 90’s, through plenty of foreign aid, the Cuban government 
was able to purchase the best of medical equipment for its healthcare system. However, when 
funding ceased, the inability to sustain such equipment resulted in 70% of the equipment being 
out of service within 7 years17. Similarly the World Bank invested about $1.5 billion in medical 
devices for developing countries between 1997 and 2001, with less than satisfactory results. 
About 30 % of the equipment proved too sophisticated for use, while those in operation had 25 to 
35 % equipment downtime due to inadequate maintainance18. This was due to the failure of the 
Bank projects to assess the cost-effectiveness and affordability of these medical devices and to 
evaluate the real impact of their investment on improving the quality of healthcare.  
Also, anaesthesia provision is still challenging in developing countries because this is a 
technology-based specialty which can be very vulnerable if resources are limited19,20,21. A recent 
study in Anaesthesia demonstrated that adequate equipment and supplies for safe aneasthesia in 
Uganda was available in only 6% of C-sections, 13% of children laparotomies and 23% of adult 
laparotomies22. Unfortunately, the donation of aneasthesia equipment has proven unsuccessful in 
most cases due to lack of access to equipment supplies such as compressed gas or liquid oxygen 
systems 23 . Table 1 summarises problems with donation of Aneasthesiology equipment in 
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developing countries by the World Federation Societies of Anaesthesiologists (WFSA), and 
some of which can be applicable to other medical device donations.  
Table 1: WFSA Summary of Problems with Donation of Anesthesiology Equipment Donation 24 
• Limited electrical supply which may be erratic, of a different voltage or not exist. 
• Lack of compressed gas or component supplies for replacement or expenditure may represent 
additional cost burden. 
• It may not stand up to an adverse environment (heat, humidity, dust) 
• There may be no expertise locally to install, commission or repair the equipment. 
• It may not be supplied with manuals or, if it is, they may be incomprehensible (not easily understood) 
or in a language which cannot be understood. 
• It may be defective on arrival or have part missing 
• Inadequate sterilising facilities 
• There may be no reliable or clean water source for cleaning 
• It may require basic-to-advanced physiological and/or pharmacological knowledge to use it. 
 
 
The mismanagement of technology, lack of user training and on-going technical support 
results in the failure of most medical donation programs. Donours can sometimes concentrate on 
volume, and be anxious to get rid of product without paying attention to condition of equipment, 
availability of parts, complete device documentation etc. Often, the failure to refurbish or repair 
used donated medical devices can lead to the shipment of defunct products. This is especially 
problematic with the practice of “spray and pray” whereby medical devices are aesthetically 
painted to look new, with no little or no device repair25.  Donour policies can fail to recognize 
recipients as equal partners in the process, can foster dependence and sometimes adopt an 
‘anything is better than nothing’ policy if their efforts prove ineffective26. The passive role that 
recipients play in this process is also problematic, especially as they cannot properly screen 
incoming devices or assess and plan if they can support the technology. 
 Due to notoriety of the problems associated with medical device donations, the WHO 
has set up guidelines to regulate medical donation practices in an effort to better coordinate 
donour efforts and their recipient countries to obtain maximum benefits from device donations27. 
Some basic considerations include evaluating the real cost of the technology, as well as 
considering if the recipient country can sustain the donated technology. When transportation and 
shipping costs are considered it might sometimes be cheaper to produce or buy materials locally 
as beneficiaries can often be burdened with custom taxes and importation issues. The costly 
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nature of purchasing and maintaining medical devices especially those with short life cycles e.g. 
syringes, catheters etc can represent an added burden to healthcare systems with limited budgets.  
2.2. Health Service Organisation and Management 
2.2.1. Health Care Policy 
2.2.1.1. Economic Aspects of Health Care 
Most industrialised (except for the US with mainly private insurance-based healthcare) 
and developing countries provide most of the healthcare to their citizens through public 
healthcare systems. Unfortunately, per capita healthcare spending (purchasing power parity) for 
most developing countries is very low. For example, in the United States, $  6,096 (the largest in 
the world) is spent per capita on healthcare, on average $2000 per capita in Europe, and less than 
$100 per capita in every one of the 35 nations with very low human development28. Chad, Niger 
and Ethiopia, countries with one of the lowest Human Development Indices, spend less than $50 
per capita on healthcare, with public expenditure of health being less than 5%28,29 (see Appendix 
B for more data details). While most industrialised countries spend about 5% on total annual 
health care on physical infrastructure, building, equipment, etc, in contrast in developing 
countries, capital expenditures accounts for about 40% - 50% of the total public health care 
budget7.  
Provision of healthcare through the private sector is thriving in developing countries, as it 
experienced an increase in growth from 8% in 1991 to 27% in 200012. However, although these 
services are comparable to those in developed countries, they are unaffordable to a majority of 
the population. Thus, with limited budgets, many developing-country governments attempt to 
offer comprehensive health care for all. Unfortunately this approach often results in inefficient 
spending. Due to the large disease burden in these countries, medical device purchases are 
dominated by public health considerations and healthcare professionals may often prioritise 
social services over medical devices12. Resources typically get concentrated in urban hospitals 
and tertiary-care hospitals, which provide the most specialised and sophisticated services, 
consuming a majority of the healthcare budget. This misallocation of funds leaves very limited 
funding towards more cost-effective public health measures especially for rural and poorer areas, 
(with a larger subgroup of the population) that have limited access to these healthcare services30.  
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The lack of proper knowledge in assessing health care needs can often lead to irrational 
procurement especially of expensive medical devices. In Columbia, a government-sponsored x-
ray distribution project failed due to lack of radiologists and unavailable electricity in some areas 
leading to equipment sitting idle for over 10 years7 31 . Developing countries can provide 
significant health benefits to a larger population by concentrating public spending on highly cost-
effective public health and clinical services, thereby protecting the health sector and its citizens 
from unnecessary healthcare expenditures. For medical devices, this requires assessing cost-
effectiveness of medical device purchases, developing policies on rational procurement and 
regulating purchasing decisions in both the public and private sectors1. A strong collaboration 
between private industry and governments is necessary as without the full support of a country’s 
government, any solution to a country’s medical problems will only prove temporary32. 
2.2.1.2. Medical Device Regulations 
As most developing countries obtain their medical devices via imports, the presence of a 
regulatory body is important to ensure quality products with pre-market, on-market, and post-
market control to ensure device safety, quality and appropriate use.  These responsibilities 
include ensuring incoming devices comply with essential safety/performance principles, are 
appropriately selected by healthcare providers for use and implementing good medical device 
management and disposal practices. Unfortunately, for most developing countries, medical 
devices are perceived as more of a procurement issue as opposed to an integral part of health 
care policy3.  
Few developing countries have an authoritative body with the sole responsibility of 
regulating medical devices, and this lack of effective regulation can lead to the importation of 
substandard devices, or illegal re-processing of medical devices. For example, the reprocessing 
of single use devices such as syringes without proper sterilisation is a major source of disease 
transmission such as HIV and Hepatitis in most developing countries33. The lack of post-market 
surveillance also makes it difficult to monitor device failures and hold manufacturers 
accountable for adverse device incidents or product recall.  
While purchasing refurbished medical equipment can be cost-saving, the lack of adequate 
medical regulatory control is problematic in most developing countries as they can often pose a 
safety risk34 , 35 . The U.S. accounts for almost half of the world’s market share in used and 
refurbished medical devices, this sector is strictly regulated by the U.S. Food and Drug 
Administration to ensure that equipment is rebuilt and tested to original specifications35. The bad 
experiences of trading in used/refurbished medical devices such as lack of after-sale technical 
support or spare parts, adequate documentation etc has led to the partial or complete ban in most 
developing countries. By 2002, at least 5 countries had imposed a total ban on the import of used 
equipment and 17 other countries have partial bans35. 
In 1993, a Global Harmonisation Taskforce was set up by the major medical device 
producing and regulatory bodies (Australia, Canada, the European Union, Japan and the U.S.A.) 
to harmonise standards and regulatory practices across countries. This was done in an effort to 
reduce regulatory barriers, facilitate trade and improve access to safe and effective technologies. 
Although in effect for more than a decade, developing countries who import 90% of their 
medical devices remain sidelined in this process due to their lack of knowledge on best practice 
guidelines36.   
To bridge this gap, the WHO published a global overview and guidance document, with 
recommendations for countries with limited infrastructure on how to build a more effective 
regulatory system34. This includes a matrix of the entire life cycle of a medical device, the 
stakeholders involved at each stage, and policies that should be in place to manage each stage in 
the medical device life cycle (see Figure 2) Most developing countries should prioritise vendor 
and product registration, user training and post-market surveillance (correct use, problem alert, 
recalls) though creation of a database, since most of them import their medical devices. Figure 3 
shows the key responsibilities of such a regulatory system during the phases of the life cycle, of a 
medical device.  
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Figure 2: Stake holders during medical device lifecycle 
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 Figure 3: Key elements of a National Medical Device Regulatory or Monitoring Programme 34 
 
2.2.1.3. Medical Device Management 
Medical devices are assets that require good management in order to fully utilize their 
capacity, given their considerable amount of capital investment, high maintainance costs and 
relatively short life spans. Also the safety and health outcome of a medical device is intimately 
linked to how well it is managed and its operator’s skills (see Figure 4). Unfortunately, the WHO 
estimates that around 50% of medical equipment in developing countries is not functioning, 
primarily due to a lack of maintainance culture in these countries3, 37 . Medical device 
management is often reduced to the mere acquisition of up -to-date technology and equipment 
depreciation and maintenance costs are hardly factored in healthcare provisions. Figure 5 shows 
(without factoring natural depreciation), the value medical devices can fall to about one tenth of 
their original value due to inadequate device procurement decisions, over sophistication, misuse, 
lack of spare parts, inadequate support infrastructure, maintainance and repairs1.   
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Figure 5: Waste of resources from budget to patient due to lack of 
medical technology management1 
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For example, Table 2 summarises the results of a small survey by Engineering World 
Health (EWH) of diagnostic x-ray availability in eight hospitals in three countries: Nicaragua, 
Haiti and Sierra Leone38. The survey documented the number of mobile and stationary, working 
and non working diagnostic x-ray machines, noting the cause of equipment breakdown where 
applicable. Only one of the eight hospitals had a working mobile x-ray machine, and 
approximately half of the hospitals had a working stationary x-ray machine. The most common 
reason cited for broken equipment was an expired x-ray tube, with unavailable spare parts. Even 
at La Mascota Hospital, the largest pediatric hospital in Nicaragua, which also conducts thoracic 
surgeries, there was no functional x-ray of any kind.  
 
Table 2: EWH Survey of X-ray machines in Sierra Leone, Haiti and Nicaragua 38 
 
 
It is also important to note that the operating and maintainance costs during the life cycle 
of a medical device can sometimes be underestimated e.g. for disposables syringes, infusion 
pumps, test strips. For example disposable, sponge-based self adhesive pads have replaced 
metallic, reusable ECG electrodes due to their convenience of being faster to use and no 
requirement for cleaning and sterilising between uses. However, when an ECG machine was 
donated to a Tanzanian hospital by EWH, reusable metallic electrodes had to be designed and 
tested due to the lack of disposable ECG electrodes in the area and budgetary constraints of the 
hospital39. Figure 6 shows that acquisition costs represent a “tip of the iceberg” in the recurrent 
costs of maintaining a medical device during its lifecycle25. It is thus important to take into 
account the budgetary constraints of resource limited healthcare settings and consider the total 
life cycle ownership costs of medical devices, which includes in addition of acquisition costs, 
costs of  accessories  and consumables, maintainance, and utilities.  
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Figure 6: Medical Device Acquisition Iceberg25 
 
2.2.2. Health Technology Transfer 
2.2.2.1. Education and Healthcare Personnel 
The proper education and training of healthcare personnel is important to ensure the safe 
and effective use of medical devices.  This includes training in preventive and routine 
maintainance for technicians as well as training of proper use of equipment for healthcare 
personnel. In most developing countries, the lack the proper training schools or technically 
qualified staff contributes to the inadequate maintainance of medical devices. The one-time 
training by the vendor prior to device use has proven insufficient, especially as the proper use of 
medical devices requires on-going support and the coordination of efforts of all healthcare 
personnel. Language barriers also create problems in terms of proper translation of technical 
documents and training into the native languages of the local population.  
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In addition, the absence of suitable personnel to integrate knowledge of medical needs 
with technical expertise presents a challenge when determining what medical devices are suitable 
for particular healthcare environments. It is important to note the significant impact of brain 
drain, where most developing countries have lost their skilled workers to greener pastures 
abroad40,41. In addition, is the phenomenon of “brain leak” where the few people who are trained 
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for specific tasks technical leave service either due to low salary incentive or lack of motivation. 
For example, at the Centre Medical Evangelique hospital in the Democratic Republic of Congo, 
two individuals who were trained to be electronic technicians for the hospital resigned due to low 
salaries42.   
2.2.2.2. Medical Device Research 
The World Health Assembly emphasises the importance of improving patient safety and 
quality of health care by strengthening the science-based systems used to assess and monitor 
medical equipment and technology. Simply reducing the price of medical devices or removing 
design features to reduce medical device costs has proven insufficient, especially as stripped-
down versions or simplicity in design can be perceived as being inferior.  Unfortunately, the lack 
of adequate technical culture in most developing countries concerning medical research and 
design remains an obstacle, especially as device development requires a significant amount of 
investment, capital and higher education.  
Developing countries can develop innovative or design capabilities to build new 
technologies for themselves through research and development, by acquisition of operational 
capabilities to duplicate and adapt technology to fit local conditions. For example, Brazil has 
worked to counter its technology independence by building on its research capacity, through 
heavy investment in education and research and development opportunities41. By encouraging 
local innovation and increasing health equipment manufacturing by 13.8%, Brazil now meets 
73% of its local demand for medical devices31.  
Creating local markets and fostering innovation is thus fundamental as developing 
countries will never be able to meet their healthcare demands through medical device imports. 
For example, developing countries have a share of only 7% of the annual hearing aid market, 
even though 80% of deaf and hearing impaired people live in this region43. In addition are the 
high costs of purchasing these hearing aids and rechargeable batteries that require electricity can 
be impractical in places with unreliable facilities. Godisa Technology Trust, a non-profit social 
enterprise in Botswana developed an affordable solar powered hearing aid battery charger, the 
Solar Aid for a digital behind-the-ear (BTE) hearing aid for use in developing countries 
(see Figure 7)44. The company also developed a low cost (55% less expensive than industry 
standard), full diagnostic, portable audiometer for testing hearing thresholds of its customers, for 
more customisable products. It is currently an ISO certified company, and its successful model of 
sustainable social enterprise has attracted interest from other countries such as Mali, Brazil, 
Jordan and Canada 44,45.  
 
 
Figure 7: Solar battery charger for hearing aids 
developed by Godisa46 
 
However, due to the current technology divide, for developing countries develop their 
technology capabilities, this requires a form of “technology transfer,” as most developing 
countries are reliant on imported equipment, knowledge, information and software47. This can be 
done by either trade in goods and services, foreign direct investment or direct trade of knowledge 
through technology licensing48. However, this technology transfer process is faced with many 
challenges, such as the asymmetric access to information, regulatory issues, patent and 
intellectual property issues or the lack to fully internalise the costs and benefits of a technology 
exchange. Implementing new technologies depend on the economic support, political 
cooperation, functional infrastructure and an understanding of socio-cultural issues and concerns 
in the context of developing countries49.  
One model of sustainable technology transfer is the establishment of long term 
collaborations between developing and developed countries. However, this process must be 
based on a concept of reciprocal exchange, with an equitable and active participation of both 
parties, preferable with the initiative from recipients as it enables better integration of new 
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concepts or technologies (see Table 3). The Sustainable Sciences Institute (SSI) in San Francisco, 
a non-profit organisation was founded in 1998 to effect appropriate transfer of laboratory and 
epidemiological technologies to developing countries. SSI helps biomedical scientists gain 
access to training, funding, information and equipment and supplies to help in their management 
of infectious diseases49.  By collaborating with the Ministry of Health in Nicaragua for over 12 
years, they were able to simplify and improve on diagnostic techniques for the diagnosis and 
management of infectious diseases such as leishmaniasis, leptospiros and dengue fever.  
 
 
 
Table 3: Principles for successful research partnership 49 
 1. Decide on objectives together 
2. Build mutual trust 
3. Share information and develop networks 
4. Share responsibly 
5. Create transparency 
6. Monitor and evaluate collaboration 
7. Dessimate results  
8. Apply results 
9. Share profits equitably 
10. Increase research capacity 
11. Build on achievements
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24 
 
25 
 
3. Health Technology Assessment 
3.1. Introduction 
Healthcare spending and costs have risen dramatically over the past years, making it 
imperative to rationalise healthcare delivery 50 . With the current innovative atmosphere, the 
novelty of some medical procedures and devices can lead to their rapid adoption and use in 
clinical practice with little or no evidence as to their improvement on patient outcomes. This 
overload of information and technology has led many healthcare professionals to turn to 
evidence-based medicine in making healthcare policy decisions51. Using clinical data to provide 
evidence to the safety and effectiveness of medical procedures provides a more effective way of 
investing in beneficial and cost-effective technologies.  
Health Technology Assessment (HTA) is a systematic evaluation of the properties and 
impact of health technology, identifying potential direct and intended consequences of 
technology, as well as indirect and unintended consequences. This entails a multidisciplinary 
assessment not only of the technical properties, safety, and efficacy of health technology, but 
also of their economic attributes, social, legal and ethical impacts52. Table 4 summarises the 
various steps involved in HTA. With evidence from clinical trials, case studies, published 
research etc, the assessment demonstrates to what extent the technology is safe, works as 
intended, and is cost effective.  
HTA in industrialised countries is usually technology-oriented, and focuses on specific 
technologies such as in the consideration of coronary angioplasty over coronary bypass, MRI vs. 
x-ray imaging, laparoscopic surgery etc 53 . In contrast, the HTA approach for developing 
countries differs significantly especially as it usually deals with healthcare systems that try to 
meet a majority of the populations’ medical needs and that acquire most of its medical 
technologies through imports.  Using a problem-oriented approach that focuses on managing 
particular problems for which alternatives exist is thus more suitable approach7. Crucial 
questions that need to be addressed include making the right choice of appropriate medical 
technologies, ensuring their proper use and examining the conditions of cost-effective and 
beneficial use. As noted earlier, the poor choice of medical devices in most developing countries 
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has negatively impacted healthcare systems especially as their mismanagement represents a 
significant waste of resources. 
Table 4: Steps in Health Technology Assessment 52 
o Identify assessment topics  
o Specify the assessment problem  
o Determine locus of assessment  
o Retrieve evidence  
o Collect new primary data (as appropriate)  
o Appraise/interpret evidence  
o Integrate/synthesize evidence  
o Formulate findings and recommendations  
o Disseminate findings and recommendations  
o Monitor impact  
 
3.2. Essential Medical Devices 
To help in the adequate procurement, planning and management of medical devices in 
developing countries, the WHO has implemented a model list of Essential Medical Devices 
(EMD) which consists of medical devices that prioritises the healthcare needs of the 
population54.  In other words, the health condition of the population defines the need for medical 
devices as opposed to a marketing approach where availability of new devices justifies new 
markets or the status-quo of possessing “up-to-date” technology. This inventory of medical 
devices will generally assume the form of a pyramid where quantity of EMD tends to decrease 
with increasing device complexity25. 
The three criteria to guide in the development of such a list are that the devices be 
necessary in the implementation of a cost effective health intervention, be effective and safe. 
Focusing on the major diseases of poverty, a template list can be created by defining appropriate 
health interventions and listing the EMD required for these interventions. Countries can thus 
create and adopt a national policy within a regulatory framework to ensure the safety and quality 
through standards and facilitate procurement and supply of these devices.  Device safety, 
appropriate use and effectiveness can be ensured through a life cycle approach that 
systematically includes maintenance, training, monitoring and vigilance reporting on medical 
devices in use. 
3.3. Example of an Essential Medical Device: Auto-disable Syringe 
Injections represent the most frequent medical procedure; an estimated 16 billion 
injections are administered in developing countries, 95% for therapeutic reasons, 3% for 
immunisation and the rest for blood and blood products, contraceptives, etc55. Unfortunately, the 
WHO reports that at least 30% of vaccine injections administered in developing countries are 
unsafe leading to infections56. These unsafe injection practices have resulted in 8-16 million 
hepatitis B, 2.3-4.7 million hepatitis C and 160,000 HIV/AIDS new cases of infection. While 
sterilisable syringes offer the advantage of reducing costs and producing less disposal products, 
the risk high of transmission of blood borne pathogens and the lack of adequate sterilisation 
facilities (in some areas, sterilisable syringes are just rinsed tepid water prior to reuse) has led to 
the preferential shift to disposable syringes 57,58. 
However, Battersby et al. note that the shift to disposables has not eliminated the 
problems associated with injection related infections or morbidity due to abuse58. As Figure 8 
shows, although sterilisable syringes have the added burden of guaranteeing sterility during use, 
disposable syringes generally require more management effort during their lifecycle. The failure 
to provide adequate supplies can sometimes force some facilities to either cancel injections, 
reuse syringes or request that patients bring their own syringes, which may not always be the 
right type.  
 
Figure 8: Level of effort and attention required by sterilisable 
and disposable syringe systems 58 
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Also, the illegal repackaging and resale of syringes still remains problematic; in a 
hospital in Pakistan, several blunt-needled and blood-stained syringes were found amongst 
opened packed syringes58. Due to the significant volume of waste, the lack of disposal and 
destruction systems represent a significant risk to the population. Children are the most 
susceptible to needle-stick if syringes are disposed in public places where they often play. It is 
also important to consider that there is also the cultural conflict in the context of disposables due 
to the general lack of a waste culture (see Appendix C for unsafe injection practices).  
  To curb the problem associated with injection related injuries and infections, the WHO 
adopted in three part strategy to address this situation. The steps involved include:  
i. Changing the behaviour of health care workers and patients to encourage safe 
injection practices, especially in the wake of the HIV pandemic 
ii. Ensuring the availability of equipment and supplies, with manageable costs on health 
care systems.  
iii. Managing waste safely and appropriately through the availability of proper waste 
management systems55. 
 
Auto-disable (AD) syringes were thus introduced to eliminate the reuse of syringes, 
especially for mass immunisation campaigns. These syringes have a built in mechanism designed 
to give a single dose of the device, after which the syringe is permanently locked or disabled. 
The Soloshot ™, the first commercialised AD syringe developed by The Program for 
Appropriate Technology in Health (PATH), has a fixed needle with a metal clip that locks the 
plunger after a single use59. Another innovative product developed by PATH is the auto-disable 
pre-filled syringe that contains a single vaccine dose (0.25-1ml of fluid) 60 . In addition to 
preventing syringe reuse, this technology enables the minimisation of vaccine waste and 
simplifies logistics by ensuring the administration of the correct dose. Drugs available through 
this platform include the contraceptive Oxytocin, tetanus toxoid and hepatitis B.  
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Figure 9: Auto-disable Syringe (a) 61and mechanism of action (b)62 
 
       
Figure 10: Pre-filled Auto-disable Syringe63-Uniject™ and schematic64 
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The WHO, UNICEF, United Nations Population Fund and the Federation of Red Cross 
and Red Crescent Societies issued a policy, with recommendations to assist policy-makers and 
programme managers to plan the introduction of these AD syringes. This policy is adopted as 
part of a comprehensive national policy and plan of action to improve injection safety, both for 
routine immunisation and for mass campaigns65. The above organisations endorsed a “bundling 
policy” in the life cycle management of these syringes that includes the good quality vaccines, 
auto disable syringes and safety boxes for disposal. Each of these components is a part of this 
theoretical bundle and cannot be considered alone. Consequently, the WHO urges donors/lenders 
that finance injectable products to finance appropriate quantities as well as sharps management 
systems55. The steps for successful auto-disable syringes are outlined below.  
The first step requires conducting an injection safety assessment to estimate the 
frequency of unsafe injection practices, as well as evaluate if healthcare facilities meet the 
minimum requirements to support equipment supplies and waste disposal. This assessment 
typically takes 2-3 weeks, and costs between US $5000-$10,000. The information obtained will 
provide baseline data that will assist policy makers in defining problems and designing effective 
and efficient injection safety interventions65. The next step involves developing an effective 
planning and management system to support the introduction of safety syringes. This includes 
policy statements, strategy, financing, supplies and annual work plans. In addition, health 
workers must be educated on the risks of unsafe injection practices and trained to administer safe 
injections and adequately dispose of waste products.  The general public must also be educated 
on the need for safe injection practices and demand appropriate services.  
 
 
Table 5: Planning Checklist for Injection Safety 65 
Develop an injection safety plan 
 
• Identify stake holders 
• Assess the situation 
• Include costs for safety in finance 
plan 
• Ensure injection safety through 
education 
• Manage sharps waste 
• Monitor and document results 
• Evaluate results and identify 
lessons learned 
Ensure vaccine delivery from 
delivery to vaccine administration 
• Use pre-qualified/national 
regulatory authority –approved 
vaccine injection materials 
• Bundle lyophilised  vaccines with 
corresponding diluents, 
reconstitution syringes, AD 
syringes and sharps boxes 
• Communicate risks associated with 
unsafe injection practices to all 
levels 
• Train health care workers in proper 
techniques 
Manage disposal of used injection 
equipment 
• Assess local environment 
regulations and options for sharps 
treatment and disposal 
• Plan storage, transportation and 
disposal 
• Identify practical, simple solutions 
• Monitor disposal on a regular and 
frequent basis  
 
In compliance with the bundling policy, it is important to establish a reliable estimate of 
equipment requirements for immunisation programmes to develop an efficient stock and 
management system. This system should guarantee minimum stock levels for the supply and 
distribution of injection equipment. Table 6 shows a three year estimate of equipment supplies 
needed for the composite for DTP-HepB-Hib vaccine (Diphtheria, Hepatitis B and H 
Haemophilus influenzae type b) based on anticipated vaccine coverage of target children. The 
estimates for all vaccines can be tallied, and the total costs and storage space requirements 
estimated. Waste disposal systems can be on-site or at a centralised location with coordinated 
disposal schedules, and the choice of type of equipment dictated by available resources. A 
budget is developed; estimating the yearly costs of injection equipment, waste disposal systems, 
maintainance and operation costs, personnel training, program evaluation and monitoring. Such a 
budget is important for the allocation of public healthcare resources as well as obtaining external 
funding.  
Table 6: Example calculation of supplies needed for DTP-HepB-Hib vaccine65 
 
   
On a regulatory level, monitoring and supervision procedures have to be established to 
ensure the implementation of safe injection practices by health workers, and provide adequate 
supplies and disposal facilities. It is also important to establish a system to monitor adverse 
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events to allow for appropriate follow-up action, especially in cases of device or vaccine recall. 
Post immunisation evaluations are also necessary to identify areas of improvement of injection 
safety and results made available to healthcare personnel for feedback.  
The introduction of AD syringes in immunisation programmes has had a positive impact 
on improving vaccination coverage rates and injection safety in developing countries66,67. In 
most cases, health workers indicated a preference for AD syringes as they minimised vaccine 
wastage,  and were faster, easier to use and more accurate than conventional disposable syringes. 
However, one major constraint has been the price of auto-disable syringes with respect to 
conventional disposable and sterilisable syringes; when initially introduced AD syringes were 
priced about three times that of standard disposables.  
Fortunately, the increased demand has attracted many manufacturers and suppliers and 
this competition has reduced the price of AD syringes to within $0.01 that of conventional 
disposables60. The UNICEF provides only AD syringes to countries requesting syringes, and 
as Figure 11 shows, there has been a steep increase in the number of syringes purchased through 
UNICEF.  Nonetheless, it is also relevant to mention cases where use of auto-disable syringes 
can be substituted with sterilisable syringes when the former represents a significant budgetary 
burden to resource-limited areas. For example, in Madagascar, a mixed programme of 
introducing AD syringe use on non-routine immunisation days proved to be more beneficial in 
reducing cost and minimising logistical complications associated with frequent sterilisation68.  
 
Figure 11: Actual and projected number of AD syringes 
purchased through UNICEF 65 
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4. Infectious Diseases 
 
Infectious diseases in developing countries still pose a significant healthcare problem, 
these countries account for 95% of the world’s disease burden69. The leading causes of death are 
from lower respiratory infections, HIV/AIDS, diarrhoeal diseases, tuberculosis, malaria and 
tropical diseases. While most of these diseases are treatable, with improved access of drugs 
through drug campaigns, the lack of adequate and appropriate diagnostics often limits treatment 
of these diseases. Improved diagnostics are needed not only to confirm/rule out clinical diagnosis 
in symptomatic patients, but also to screen high risk individuals with asymptotic diseases. For 
example, fetal death from congenital syphilis can be prevented if infected mothers are identified 
through serological antenatal screening and treated appropriately by the middle of the second 
trimester70. The over treatment or over prescription of drugs through mass distribution with no 
confirmatory diagnosis has contributed to the increase in resistant micro-organisms, resulting in 
increased disease complexity and treatment costs of some diseases. For example, the overuse of 
the cheap anti-malarial chloroquine and increasing tuberculosis resistance has resulted in the 
shift towards more expensive class of compounds for treatment71,72.  
Identifying the testing resources and capabilities of healthcare systems is an essential step 
in establishing the user requirements for newly developed test methods which must be met in 
order to successfully implement these newly developed diagnostics. Assuming the centralised 
laboratory model found in developed countries is thus not applicable for test development in 
developing countries. Girosi et al. identified through literature search, three categories of 
resource distribution common to developing countries: no laboratory infrastructure, minimal 
infrastructure and moderate to advanced laboratory infrastructure73 . Table 7 summarises the 
characteristics of these three infrastructural levels based on the availability of electricity and 
clean water, physical infrastructure and staff.  
These infrastructural characteristics impose constraints on test developers as they dictate 
the selection of the appropriate specimen types, biomarkers and the pathogen detection technique 
used. Settings with no-infrastructure thus represent the most challenging for diagnostic 
development, especially as rapid answer tests are desirable for immediate patient treatment. The 
unreliability of electricity and access to clean water and cold storage thus rules out the usage of 
many popular tests that would be adequate with these resources. Robust diagnostic tests that are 
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simple to use and require minimal expertise/training and meet the required test performance are 
preferable, as they can be applied to a broad range of settings.  
 
Table 7: Health-care settings as defined by infrastructure categories73 
Characteristics No Infrastructure Minimal 
Infrastructure 
Moderate 
Infrastructure 
Advanced 
Infrastructure 
Examples of 
actual locations 
In the community or 
home 
Health clinics 
(Africa), rural health 
clinic (Asian and 
Latin America) 
Hospitals (Africa),  
urban health clinic 
(Asian and Latin 
America) 
Hospitals (Latin 
America and Asia) 
Electricity Not available Not reliably 
available 
Available Available 
Clean water Not available Not reliably 
available 
Available Available 
Physical 
Infrastructure 
None None or minimal 
laboratory  
Poorly equipped 
laboratory 
Well equipped 
laboratories  
Staff No expertise Nurses (minimal 
expertise available) 
Nurses, some 
physicians, poorly 
trained technicians 
Nurses, physicians, 
well trained 
technicians 
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5. Diarrhoeal Infectious Diseases 
5.1. Introduction 
Diarrhoea is a manifestation of intestinal dysfunction that results in increased stool output 
with loss of water, electrolytes and/or nutrients. Infectious diarrhoea is due to an etiologic 
pathogen, often accompanied by additional symptoms such as nausea, abdominal cramps and 
vomiting.  Infectious diarrhoeal diseases are the second leading cause of morbidity and mortality 
worldwide, with over, with over 85% of cases in developing countries mainly due to areas poor 
environmental sanitation conditions74. Children are the most susceptible to diarrhoeal infections, 
with over 1 billion diarrhoeal episodes and 2-2.5million deaths occurring in children younger 
than 5 years of age 75 . Some common pathogens associated with infectious diarrhea are 
Escherichia coli (E. coli), Shigella spp., Salmonella spp and Vibrio cholerae. 
 The major therapeutic intervention for diarrhoea consists of fluid and electrolyte therapy. 
The introduction of simple and cheap oral rehydration therapy solution (fluid containing of salts 
and glucose) in developing countries has contributed to the significant decrease in diarrhoeal 
associated deaths76. In addition, is the control of diarrhoea through personal and general hygiene 
(e.g. washing hands), with access to clean water, clean food and appropriate sanitation facilities 
Antimicrobials  are indicated for patients with select bacterial and protozoal pathogens74. This is 
because most enteric infections are self limited and treatment might prove ineffective in some 
case. In addition, there is growing concern of drug resistance of major enteric pathogens like 
Shigella spp and E. coli due to unnecessary and excessive use of antimicrobials.   
Diarrhoeal outbreaks can be controlled with proper diagnosis and rapid treatment through 
vaccination and syndromatic case management. Constant monitoring of pathogen susceptibility 
patterns is also important in selecting appropriate therapies when indicated. Assessment of stool 
characteristics is a key feature of identifying pathogens causing diarrhoeal. However, the 
standards used for diagnosis in developed countries (culture, enzyme immunoassay and PCR) are 
impractical, expensive and too slow for developing-world users. The need of a non-centralised, 
point-of-care solution that is rapid, low maintainance, easy to use and sensitive and accurate is 
important for management of disease. Figure 12 shows the development process of a new 
diagnostic from discovery research to test use. 
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and health impact 
‐ Negotiated pricing 
Figure 12: Diagnostic test development from research to test use: steps, barriers and solutions77 
 
5.2. Diagnostic Development 
5.2.1. Research and Development Funding 
Although the costs of diagnostic development are relatively cheaper than those for drugs, 
the lack of capital resources by most developing countries remains an important design 
constraint. Fortunately, the past few years has seen an increase in investment in designing 
healthcare technologies to address the specific needs and unique characteristics of the developing 
world. PATH HealthTech and the Lee’s diagnostics development programme at the University 
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of Cambridge, UK are currently working on diagnostic development for developing countries 
market, with funding enabled through the Bill and Melinda Gates Foundation78. Dr Paul Yager at 
the University of Washington is working in collaboration with PATH and other collaborators to 
develop in vitro diagnostics for developing countries. Funding for diagnostic development is also 
available though the US National Institute of Allergy and Infectious disease, though primarily 
motivated by biodefence concerns of the potential weaponisation of disease pathogens78.  
5.2.2. Market Analysis and User Requirements 
As noted earlier, the successful implementation of diagnostics in the developing world is 
dependent on the ability to define and meet user requirements (see ASSURED method developed 
by WHO). PATH is mainly responsible for performing market analysis and evaluating user need 
assessments. The first task involves rationalizing the development of the diagnostic technology, 
by assessing the need and the health impact of the developed technology79,80. This involves 
establishing the effect of a diagnostic tool on reducing the disease burden which requires disease-
specific modeling of the status quo and changes that would occur upon introducing the new 
diagnostic in a certain setting. By estimating the percentage of the population that will have 
access to this new technology, the health impact can be determined using different health 
outcomes. The second task involves defining the user requirements which involves identifying 
their capabilities at the different levels of the healthcare systems, and estimating the patient’s 
access these facilities.   
Ricci et al. investigated the potential impact of a rapid diagnostic test to identify specific 
causes of acute diarrhea, especially in reducing stunting in children < 5years 81 . Recurrent 
diarrhoeal illnesses in these children have been shown to represent a risk in stunting, with G. 
lambia, C. parvum and EAggEC being the most implicated pathogens. Figure 13 illustrates the 
probability tree model they utilised for the introduction of a new diagnostic in comparison with 
the status quo. First, there is the probability that a child presenting with diarrhoeal symptoms will 
seek care, and this course of action usually depends on prevalence of the condition and severity. 
This individual seeking care will enter the health care system at different levels of the healthcare 
systems depending on accessibility. For the given test this will result in different test outcomes 
(true positive, false positive, false negative or true negative), with probabilities that depend on 
test characteristics and prevalence of the disease condition. Based on the test outcome, patient 
will follow different treatment trajectories leading to one or more eventual health outcomes (see 
Appendix D for summary of model parameters). 
 In the ideal situation, children who have access to the new diagnostic and a health care 
provider that are tested positive for at least one pathogen receive a pathogen specific treatment 
and nutritional supplement. Those who test negative receive standard treatment which is 
typically oral rehydration therapy. Based on their analysis, Ricci et al. concluded that a test 
requiring minimal infrastructure that is 90% sensitive and 90% specific for each of the above 
pathogens can reduce stunting by 12.5% and save 2.8 million disability adjusted life years 
(DALY). This assumes a cost of treatment of $6 and positive externalities associated with 
treatment equal to 0.25 DALYs.  
 
Child aged 0‐5 years
Status quo
New Diagnostic
No diarrhoea
Has some
pathogens
Diarrhoea
Sees provider
No care
Has access to new 
diagnostic
No access to new 
diagnostic
No diarrhoea
Diarrhoea
No care
Sees provider
Test ‐ for all three 
pathogens 
Test + for at  least 
one pathogen
Does not have
any pathogens
Has some
pathogens
Does not have
any pathogens
 
Figure 13: Probability tree for modelling diarrhoeal disease pathogens to reduce stunting in children81 
  
The diagnostics test should be developed for use in settings with minimal infrastructure 
with limited staff as this allows for the flexibility of the device to be used in settings with more 
advanced infrastructure. The diagnostic test should be simple to operate, require little 
maintainance and withstand ambient temperature and dust. The non-reliability of electricity 
necessitates that hardware be battery-operated and the reaction procedure require minimal power. 
The cost of the disposable should be within a range $1-$5 and an inexpensive reader ranging 
from $100-$200. To reduce transportation issues, the device needs to be light-weight with little 
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to no fluids to add on to device bulk. Given the volatility of laboratory supplies, the reagents 
need to be incorporated in the device, preferably in dry form.  
 A qualitative test result is preferred as opposed to a quantitative one, with the availability 
of a print out of the results for health records. Faeces samples are preferred for the test; with 
biomarkers such as include organism antigen, host factor adhesion factors. There is also the 
promising innovative approach of using specific volatile organic compounds from vapour that 
emanates from the feaces in diarrhoea patients as a more user friendly approach to diagnostics. 
The specificity and sensitivity for the tests should both be greater than 90%. The results turnover 
time should be less than an hour to allow for same day treatment, as a more aggressive goal 
towards reducing the probability of patient leaving the testing site prior to treatment. 
5.2.3. Diagnostic Methods for Diarrhoeal Infectious Diseases 
5.2.3.1. Stool Analysis 
Stool microscopy and culture is commonly used to identify microbial or parasitic 
infections. Stool can be collected in a bottle or using a rectal swab. A microscopic exam of the 
stool following can be done to examine its appearance or the presence of pus (e.g. increased 
leucocytes) or blood (e.g. red blood cells) as this can often indicate the presence of an invasive 
pathogen82. Gram stains can be used to reveal the presence of unique pathogens, where gram-
positives stain blue with gram the stain. The gram negative bacteria don’t retain the stain, and are 
thus counterstained with another colour.  For example, E. coli (see Figure 14) and Shigella are 
both gram negative. The problem with the gram stain is that it can be inconclusive if the 
laboratory physician is not well trained to identify pathogens based on their morphology. The 
stool sample can be cultured for a few days, on differential or selective media that favour the 
growth of certain pathogens to isolate and identify specific pathogens.  
5.2.3.2. Enzyme Immunoassay 
When present in the body, microorganisms induce an immune response, whereby 
antibodies are produced to bind specifically to them and help in facilitating their elimination 
from the body.  Enzyme Immunoassay (EIA) is based on antibody-antigen recognition 
(see Figure 15). A surface is coated with an antibody, which binds specifically to a diarrhoeal 
pathogen. An enzyme-labeled antibody that also binds to that same antigen is later introduced. 
The enzyme attached to the second antibody catalyses the conversion of a reactant to a product, 
and this can be visualised by colour change. Hence, this provides a qualitative confirmation of 
the presence of a pathogen 
 
    
B A 
Figure 14: E. Coli Gram stain (a)83 and culture (b) 84 
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Figure 15: Enzyme Immunoassay Assay Principle85 
 
5.2.3.3. Polymerase Chain Reaction 
The Polymerase Chain Reaction (PCR) is based on the ability of nucleic acids to bind to 
each other due to complementary pairing of their nucleotide sequences. The DNA or RNA of the 
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pathogen can be extracted, isolated and separated to single strands. Using a primer, an alternate 
nucleic acid strand can be synthesised in the presence of nucleotides, using a polymerase 
enzyme. This process requires an alternating temperature cycle, hence the need to control 
temperature during the reaction (e.g. using a thermocycler). 
 
 
Figure 16: Polymerase Chain Reaction86 
 
5.2.3.4. Point of Care Diagnostics 
Point-of-care (POC) diagnostics development is preferred as the short result turn over 
time allows for quicker patient treatment, limiting the amount of return visits by patients. POC 
tests offer the advantage of rapid visual results of antigen/antibody detection, cheaper 
production, use of minimal expertise and equipment 87 . However, there is still the need for 
improved POC tests to meet the needs of these disease-endemic areas, due to the failure of some 
these tests to perform with adequate sensitivities in controlled clinical trials. The WHO 
developed a list of general characteristics as a framework for the development of appropriate 
diagnostic tests for resource-limited areas, abbreviated as ASSURED, that serves as a template 
for diagnostic development for developing countries (see Table 8).  
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Table 8: Characteristics of ideal diagnostic test for the developing world88 
• Affordable by those at risk of infection 
• Sensitive (few false negative results) 
• Specific (few false positive results) 
• User-friendly (simple to perform by persons with little training 
• Rapid treatment at the first visit, and robust without need for special 
storage 
• Equipment-free (no large electricity dependent instrument needed to 
perform test, portable handheld  battery operated devices acceptable) 
• Delivered to those who need it
 
Nanotechnology has allowed for the miniaturisation of complex chemical reactions into 
small, self contained packages or lab-on-chip based plat forms. Often described as the fluidic 
equivalent of electronic circuits, biomedical applications of micromechanical systems 
(BioMEMS) or microfluidics represent a promising diagnostic test platform especially as 
miniaturisation can offer faster response and simplification of analysis procedures. Dr. Paul 
Yager at the University of Washington in collaboration with PATH and other researchers are 
currently working on a “disposable with reader” diagnostic platform to simultaneously detect 
common enteric pathogens. This diagnostic assay comprises a credit-sized multiplex disposable 
enteric card with microfluidic circuit channels filled with chemicals/reagents needed for 
translating the stool/blood sample into a diagnosis. The sample is injected into the card and 
inserted into a hand-held instrument to control the card's temperature.  
5.2.4. New Diagnostic Technology: BioMEMS 
Stool culture requires the availability of well trained and supervised technologists and 
limited by the expenses for the supply of reagents, electricity and equipment maintainance. The 
time consuming nature of cultures (hours to several days) can often lead to patient impatience 
and the inability of the healthcare personnel to follow up treatment.  Although EIA as on nucleic 
acid amplification techniques (NAAT) can be performed in few hours (e.g. 3-4 hours) and have 
more sensitivity and specificity, they generally require expensive specialised equipment. For 
example, PCR reactions require thermal cycling through alternative heating and cooling of 
samples in thermocyclers89. 
Microfluidics deals with the behavior, precise control and manipulation of fluids that are 
geometrically constrained to a small, diameter scale, typically < 1mm 90 . One of the main 
advantages of this platform is that the multiple steps of a chemical process can be integrated into 
a monolithic lab-on-chip disposable. The diagnostic platform thus consists of a credit-card sized 
disposable and an electronic instrument reader to control reaction (see Figure 17).  The user 
inserts a swab containing the stool sample into the DEC which is places in an instrument to 
control the reactions. The device can also incorporate on-chip control of thermo-pneumatic 
pumps, micro-heaters and temperature sensors, miniaturised fluorescence detectors, 
sample/analyte concentrators and filters. 
 
 
Figure 17: Disposable Enteric Card 91 
 
 The DEC is thus compatible with small sample/reagent size (50- 100 µl) and multiple 
tests can be processed in parallel on a single chip, minimizing waste. This platform also provides 
for more precise, accurate and reproducible tests when compared to assays performed by hand as 
there is less liquid transfer error. This card includes four microfluidic subcircuits for organism 
capture and lysis from raw stool, nucleic-acid capture, multiplexed nucleic-acid amplification, 
and visual detection of amplified PCR products with display of results92. Figure 18 shows a 
schematic diagram of a laminated card showing the separate compartments for the reaction; the 
card includes silica filters and microfluidic valves to automate fluid movement in the device.  
The sample is displaced via the microfluidics channels via a combination of capillary 
action and positive displacement pumping. Bacterial agents are identified via specific antigen 
capture by magnetic beads conjugated with selective antibodies from stool samples. 400 clinical 
samples of pathogenic stools infected with E. coli 0157, Shiga toxin-producing E. coli (STEC), 
Shigella dysenteriae, salmonella spp., and campylobacter spp. was collected by PATH and used 
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for product development93. Information on the sample origins, how they are stored as well length 
of storage are important.  
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Figure 18: Schematic diagram of a disposable enteric card94 
 
 
After extracting nucleic acids from the pathogen, specific virulence genes are amplified 
for accurate identification. The device includes a positive and negative control to demonstrate 
proper sample processing and validate results. As shown in Figure 19, multiple enteric pathogens 
can be detected from the same stool sample using immunocapture. The complete reaction 
sequence will take less than 30 minutes. Early tests have shown that comparable sensitivity and 
specificity results to tests performed with conventional microbiological and PCR assays95.  The 
use of dry-reagent storage for this card has also been demonstrated whereby the activity of the 
reagents was retained upon re-suspension with water94.  
Another advantage of this platform is that is allows for low cost mass fabrication via 
rapid prototyping using CO2 laser printing96. The DECs are manufactured by stacking polymeric 
sheets (4-12 sheets) that are individually designed via AutoCAD to create their 3-dimensionally 
architecture. Moving from CAD design to product can thus take less than 4 hours expedites 
laboratory testing                            
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Figure 19: Parallel testing in a disposable enteric card94 
 
5.2.5. Evaluation Trials 
5.2.5.1. Evaluation Study Design 
It is not uncommon for diagnostic test to perform below their performance characteristics 
in clinical settings. Following laboratory proof-of-principle testing, are field trials to evaluate the 
performance of the developed diagnostic. This enables the diagnostic to be tested in a real-world 
setting, which in addition to testing specificity, sensitivity and reproducibility, also incorporates 
additional such as human factors (e.g. user friendliness, proper use), healthcare infrastructure and 
climate. These external factors can significantly affect the diagnostic test performance.  
Evaluation of the diagnostics in settings generally includes two phases: a series of small 
case control designs with a minimum of 100 patients in each series, followed by a more large 
scale prospective study with a minimum of 300 subjects to validate test results. The important 
elements in designing an evaluation protocol include97,98:  
• Defining the need for a trial and trial objectives 
The evaluation protocol should state a rationale for the evaluation and the objective of the 
study. This includes identifying a problem e.g. the need for a rapid screening to 
distinguish between infectious and non infectious diarrhoea in patient that present with 
symptoms to enable same day treatment of patient.  
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• Study Site 
This includes a description of the local diarrheal epidemiology (causative species, 
endemicity and most affected age groups), climate condition and workplace conditions at 
site.  In addition, a description of the type of clinical setting and the type of staff available 
at each setting 
• Study Population 
The target population for use of the diagnostic test should be clearly defined, taking into 
account the test purpose e.g. replacement for an existing test.  The diagnostics test should 
generally be accessible and affordable to this population, if not the evaluation is deemed 
pointless.  
• Recruitment process 
There are generally two circumstances under which individuals that will be recruited 
during the prospective studies of diagnostic evaluation: screening for individuals 
presenting with diarrheal symptoms patients or distinguishing between infected and non-
infected individuals of the population, irrespective of visibility of symptoms. In the 
former, this enables the dispensation of the proper intervention by identifying the 
pathogen. The later is generally used for drug-resistant disease surveillance in monitoring 
susceptibility patterns of diarrheal pathogens. Participants must have informed consent, 
and consent forms have to be clear, concise, and in a language understandable to the 
patient. Patient information collected should include sex, age, duration of illness, 
previous diarrheal history and onset of symptoms.  
• Test under evaluation 
This includes a record of details of the test being evaluated: manufacturer, batch number, 
date of manufacture, packaging type and inclusion of dessicant etc.  
• Reference Standard 
Stool samples collected from consenting patients from either bulk stool or a rectal swab. 
A reference standard with high specificity and sensitivity is used in conjunction with 
newly developed diagnostic test for comparison. For diarrheal infections this is typically 
a stool microbiology analysis and bacteriological culture99, 100, 101.  
• Test Organisation 
The testing protocol should be developed, based on the individuals who will administer 
the test. This includes the necessary qualification and a description of training if required.  
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The characteristics of the diagnostic test evaluated are summarised in Table 9. 
Table 9: Test characteristics evaluated for diagnostic testing102 
Characteristics  
Test performance • Test sensitivity, specificity 
• Positive and negative predictive values 
Ease of use • Number of processing steps for device use 
• Need for accurate timing 
• Amount of user training required 
Conditions of use • Climate conditions 
Conditions of storage • Storage temperatures 
• Effect on test accuracy 
Shelf life • Shelf life length 
• Supply chain and expiry date  
 
5.2.5.2. Recording, Analysing and Interpreting Evaluation Results 
Results from the reference standard and new diagnostic test should be recorded separately 
to ensure independent interpretation of results, with double data entry to minimise error. Both 
results can then be compiled in a spreadsheet using information on a limited set of variables. 
Statistical tools are used to quantify test performance. As stated earlier, diarrheal diagnostic test 
for developing countries should have a specificity and sensitivity greater than 90%.  A 2x2 table 
is used to evaluate test performance based on classification of samples results from both tests to 
calculate test sensitivity and specificity. 
 
Table 10: 2x2 table to evaluate test performance103 
Test under evaluation Reference  Standard Test 
          Positive                              Negative 
Positive  TP FP 
Negative FN TN 
TP= Sensitivity (Pretest Probability) 
FP= (1-Specifity) (1-Pretest Probability) 
FN= (1-Sensitivity) (Pretest Probability) 
TN= (Specify) (1-Pretest Probability) 
 
FPTN
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However, it is important to note the effect of sample size on test these two characteristics 
as increasing sample size often reduces these estimates. Thus the inclusion of a 95% confidence 
interval (i.e. a 95% confidence that the interval contains true values of sensitivity and specificity) 
calculated using the formula below:  
n
pppervalconfidence )1(96.1int_%95 −±=  
Where p=sensitivity (specificity measure) measured as a proportion, n=number or infected people (or 
specificity, from uninfected people) 
 
5.2.6. Cost Analysis 
The recurrent cost associated with diagnostics cannot be ignored due to their short 
lifecycle. It is also important to demonstrate especially to the local government and public health 
care sector that the impact of a newly introduced diagnostics is substantial with absorbable costs, 
especially if alternative already exists. This cost analysis can be calculated via three methods104: 
• A cost analysis that calculates total expenses incurred for use of the new 
diagnostic test including personnel, facilities, overhead, equipment, sample 
collection and reagents 
• A cost benefit analysis that calculates the net cost i.e. cost of a correct diagnosis 
– benefits from reaching correct diagnosis. These benefits which include averted 
treatment costs, averted losses due to illness, and less tangible costs (e.g. reduced 
patient pain and suffering) are assigned a monetary value.  
• A cost-effectiveness analysis which calculated the cost of a diagnostic and 
compares it to a resulting health outcome e.g. deaths or illnesses averted, DALYS 
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saved etc. Results from both the new diagnostic and reference standard can be 
compared.  
5.3. Challenges to Enteric Diagnostic Test Development 
5.3.1. Regulatory Standards and Guidelines 
Potential diagnostic failures include incorrect medical decision and action due to 
inaccurate results, device malfunction, erroneous results due to environmental effects, or non-
indicated use25. This can be due to either to product defect, design defect, product misuse or user 
negligence25.The lack of regulatory standards for diagnostic tests in the developing world is 
another major constraint in diagnostics development. As a result, developing countries are often 
susceptible to purchase poor performance tests especially as there is no formal evaluation of their 
performance and effectiveness or submission of clinical trial data. A recent 2001 global survey 
by WHO revealed that more than half of its 191 member countries reported no regulations for in 
vitro diagnostics, with most countries being from the developing world102. Even when mandated, 
there is the lack of national and international clinical trial guidelines for diseases prevalent in 
developing countries. Previous standards established by the US Food and Drugs Administration 
(FDA) and the European Union are not applicable for use in developing countries. Peeling et al. 
note that plans for international standards for regulatory approval of diagnostics in developing 
countries are still in the distant future102.  
5.3.2. Accessibility to Tests 
The collaboration between public healthcare sector and commercial enterprises is 
important in ensuring affordable costs and the sustainable supply of high quality diagnostics in 
developing countries. As noted earlier, suppliers will be attracted to markets where there is 
perceived and guaranteed demand for their products i.e. the consumers’ willingness and ability to 
buy, despite the need of diagnostic technologies designed for developing countries. The 
commercial appeal of a product is also improved, if it can be applicable to both developing and 
developed countries.   
PATH works in collaboration with companies to help them lower risk of introducing new 
health technology products by recognizing the capitalistic profit-making sensibilities of 
diagnostic device manufactures especially in these deemed unattractive markets 105 . The 
organisation also partners with public-sector organisations to guarantee product demand by 
conducting market studies on users’ need and exploring potential manufacturing and distribution 
options. As such, affordable pricing can be negotiated to improve accessibility to resource-poor 
end users. Also, developing countries can purchase health care products through third parties 
such as the United Nations Population Fund which relies on technology assessments carried out 
by the WHO91.   
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6. Conclusion 
6.1. Diagnostic Tests Development for Diarrheal Infections 
The development of appropriate diagnostic technologies for diarrhoeal infections is important 
for disease case finding and management as well as for improved disease surveillance. The key 
attributes for the successful development of microfluidics diagnostic for diarrheal infections 
include:  
• Education on health issues: A high perceived need for the test with demonstrated 
feasibility, usefulness, sustainability and positive health impact to the public sector 
• Cost of technology: The cost of the disposable should be within a range $1-$5 and an 
inexpensive  electronic reader ranging from $100-$200  
• Degree of accuracy: Test specificity and sensitivity for the tests greater than 90%. 
Faeces samples, biomarkers such as organism antigen and volatile organics and dry form 
reagents 
• Quality control: Reproducible chip performance using an on chip calibrator 
• User friendliness: Developed for healthcare settings with minimal infrastructure, with a 
user interface that requires minimal user training and maintainance. A qualitative display 
of results with the availability of a print read out  
• Result turnover time: <1 hour to allow for same day treatment 
• Test performance in various setting/ operational conditions: The ability to withstand 
harsh climatic conditions with preference to preference to heat stable reagents and moist 
proof packaging, battery operation requiring minimal power consumption  
• Regulation: The establishment of a regulatory body for pre-market, in-market and post 
market surveillance to guarantee the availability of quality products and  their safe and 
effective use of products  
• Accessibility: The establishment of network for adequate distribution and supply of 
products 
• Availability of successful diarrhea therapies 
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6.2. Medical Device Development for Developing Countries 
The reliance of developing countries on imported medical devices has had a significant 
negative impact on their healthcare systems, due to the inability of these devices to be properly 
integrated and diffused within these systems. Most medical devices assume well functional 
health infrastructure and supporting systems. In addition, the high costs of purchasing and 
maintaining medical devices can stretch the resource-limited budgets of the public sector as it 
tries to offer comprehensive healthcare services to a majority of the population. Making cost-
effective and informed procurement decisions, based on the ability to sustain the devices in the 
long term is thus imperative. It has been demonstrated that one approach of introducing 
sustainable technologies in developing countries is for the public health sector to define the need 
and guarantee demand, as this offers incentive of return of investment for manufacturers. This 
public-private sector partnership provides the opportunity for risk-sharing especially as 
manufacturers enter these new markets. 
Adapting or developing new technologies for developing countries requires a significant 
amount of investment that may be unaffordable to most developing countries. The role of 
external funding from private organisations, foreign governments and non-profit organisation in 
this development process is thus important. Donour interest in a new technology is motivated if 
there is clear demonstration of the need of a technology and that its introduction and diffusion 
will be sustainable and derive significant benefits in improving healthcare outcomes. A need-
assessment of the population is thus imperative to estimate potential impact of the technology 
and establish and define performance characteristics based on the capabilities of their healthcare 
systems. As such, the device user is involved in the development process and enables testing and 
better refinement of the desired device characteristics. Following prototype development, are 
field evaluation trials to demonstrate the intended performance and adequate use of the device 
within the developing country setting.  
Sustaining technology is not only dependent on its acceptance and mainstreaming by the 
public sector but also on the availability of adequate supplies through distribution networks. 
Third parties such as the WHO or PATH can serve as a bridge between developing countries and 
medical device suppliers, especially in negotiating affordable pricings. The existence of a strong 
regulatory body is thus necessary to guarantee the purchase of quality medical products as well 
as to ensure their safe and effective use through the implementation of good management 
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practices, user training and post-market monitoring. Ultimately, by building on their research and 
development capabilities, developing countries can one day be able to meet their medical device 
needs by acquiring of operational capabilities through proactive technology transfer, to duplicate 
and adapt technology to fit their local conditions.  
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Appendix B 
 
Table 12: Human Development Report 2007 Data 
HDI rank 
HDI  value 
2005 
Life expectancy 
at birth, 
annual 
estimates  
(years) 
2005 a 
GDP per 
capita 
(PPP 
US$) 
2005 
Public expenditure 
on health  
(% of GDP) 
2004 
Private expenditure 
on health  
(% of GDP) 
2004 
Health expenditure 
per capita  
(PPP US$) 
2004 
High Human Development      
3  Australia   0.962 
 
 80.9 
 
31,794    6.5     3.1   3,123 
 
11  Finland   0.952 
 
 78.9 
 
32,153    5.7     1.7   2,203 
 
12  United States   0.951 
 
 77.9 
 
41,890b    6.9     8.5   6,096 
 
16  United Kingdom   0.946 
 
 79.0 
 
33,238    7.0     1.1   2,560 
 
17  Belgium   0.946 
 
 78.8 
 
32,119    6.9     2.8   3,133 
 
21  Hong Kong, China (SAR)   0.937 
 
 81.9 
 
34,833     ..        ..        ..    
 
35  Qatar   0.875 
 
 75.0 
 
27,664c,
d 
   1.8  
 
   0.6  
 
  688  
 
46  Uruguay   0.852 
 
 75.9 
 
9,962    3.6     4.6    784  
 
52  Mexico   0.829 
 
 75.6 
 
10,751    3.0     3.5    655  
 
61  Saudi Arabia   0.812 
 
 72.2 
 
15,711e    2.5     0.8    601  
 
65  Mauritius   0.804 
 
 72.4 
 
12,715    2.4     1.9    516  
 
70  Brazil   0.800 
 
 71.7 
 
8,402    4.8     4.0   1,520 
 
Medium Human Development      
75  Colombia   0.791 
 
 72.3 
 
7,304e    6.7     1.1    570  
 
83  Armenia   0.775 
 
 71.7 
 
4,945    1.4     4.0    226  
 
86  Jordan   0.773 
 
 71.9 
 
5,530    4.7f    5.1f   502  
 
90  Philippines   0.771 
 
 71.0 
 
5,137    1.4     2.0    203  
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112  Egypt   0.708 
 
 70.7 
 
4,337    2.2     3.7    258  
 
115  Honduras   0.700 
 
 69.4 
 
3,430e    4.0     3.2    197  
 
118  Guatemala   0.689 
 
 69.7 
 
4,568e    2.3     3.4    256  
 
128  India   0.619 
 
 63.7 
 
3,452e    0.9     4.1     91  
 
130  Lao People's Democratic Repu
blic  
 0.601 
 
 63.2 
 
2,039 
 
   0.8  
 
   3.1  
 
   74  
 
135  Ghana   0.553 
 
 59.1 
 
2,480e    2.8     3.9     95  
 
142  Nepal   0.534 
 
 62.6 
 
1,550    1.5     4.1     71  
 
143  Madagascar   0.533 
 
 58.4 
 
 923     1.8     1.2     29  
 
144  Cameroon   0.532 
 
 49.8 
 
2,299    1.5     3.7     83  
 
147  Sudan   0.526 
 
 57.4 
 
2,083e    1.5     2.6     54  
 
Low Human Development      
169  Ethiopia   0.406 
 
 51.8 
 
1,055e    2.7     2.6     21  
 
170  Chad   0.388 
 
 50.4 
 
1,427e    1.5     2.7     42  
 
174  Niger   0.374 
 
 55.8 
 
 781e    2.2     2.0     26  
 
Notes:  
a. The HDI rank is determined using HDI values to the sixth decimal point.  
b. For purposes of calculating the HDI, a value of 40,000 (PPP US$) was applied.  
c. Data refer to a year other than that specified.  
d. Heston, Alan, Robert Summers, and Bettina Aten. 2006. “Penn World Table Version 6.2.” University of Pennsylvania, Center for 
International Comparisons of Production, Income and Prices, Philadelphia. [http://pwt.econ.upenn.edu/]. Accessed June 2007. Data differ 
from the standard definition.  
e. World Bank estimate based on regression.  
f. Data refer to a year or period other than that specified, differ from the standard definition or refer to only part of a country.  
Source:  
column 1: calculated on the basis of data in columns 6-8; see Technical note 1 for details.  
column 2: UN (United Nations). 2007e. World Population Prospects 1950-2050: The 2006 Revision. Database. Department of Economic and 
Social Affairs, Population Division. New York. Accessed July 2007, unless otherwise specified.  
column 3: World Bank. 2007b. World Development Indicators 2007. CD-ROM. Washington, D.C., unless otherwise specified; aggregates 
calculated for HDRO by the World Bank.  
column 4: World Bank. 2007b. World Development Indicators 2007. CD-ROM. Washington, D.C.  
column 5: World Bank. 2007b. World Development Indicators 2007. CD-ROM. Washington, D.C.  
column 6: WHO (World Health Organization). 2007a. Core Health Indicators 2007 Database. Geneva. [http://www.who.int/whosis/database/]. 
Accessed July 2007. 
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Appendix C 
 
Unsafe Injection Practices57 
• Inappropriate and overuse of injectable medications 
• Reusing disposable needles and syringes 
• Loading syringes with multiple doses and injecting in many people consecutively 
• Using one syringe for many patients without changing the needle for each patient ( a 
practice used in some childhood immunisation programs 
• Using multi-dose vials pierced with a single drawing-up needle 
• Flaming needles between patients 
• Re-capping needles 
• Flushing needles and/or syringes with disinfectant or water to clean them after use or 
between patients 
• Not discarding the needle immediately after use at the place of use 
• Leaving contaminated sharps to be disposed of by someone other than the user 
• Separating the needle from the syringe prior to disposal 
• Bending the needle after use to eliminate the risk of reuse 
• Placing hands into containers of used needles for cleaning and sorting 
• Soaking used needles and syringes in sodium hypochlorite solutions 
• Inadequately monitored needle and syringe cleaning and sterilisation practices 
• Sharpening needles for reuse 
• Discarding needles and syringes into general waste systems 
• Collecting used needles/syringes for resale 
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Appendix D 
 
Table 13: Main model parameters for diarrhoeal diagnostic development 81 
 
Parameter 
Africa Asia Latin America 
Base  Range  Base  Range  Base  Range 
Epidemiology and prevalence   
Population aged <5 yrs (millions)  142 357 57 
Diarrhoea prevalence (3 month period)  96% 80‐100% 84% 70‐95% 82%  70‐95%
Prevalence of C. parvum  4.4% 1.7‐7.2% 4.8% 1.7‐8% 7.8%  2.7‐12.8%
Prevalence of G. lamblia  10.4% 3.7‐17.2% 7.7% 2.7‐12.8%  16.7%  5.9‐27.6%
Prevalence of C. EAggEC  20% 10‐30% 20% 10‐30% 20%  10‐30%
Average stunting prevalence (aged <5yrs)  34.5% 31.7‐37.4% 25.7% 22.5‐28.9%  11.8%  7‐17%
# of stunted children aged < 5yrs (millions)  48.5 92.4 6.5 
Healthcare access   
Proportion of children with diarrhoea visiting 
health facility 
31% 20‐40% 49% 35‐65% 32%  20‐40%
Healthcare outcomes   
Efficacy of treatment  50% 25‐75% 50% 25‐75% 50%  25‐75%
Differential risk of stunting for children with 
diarrhoea 
3 1.5‐4.5 3 1.5‐4.5 3  1.5‐4.5
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